Supreme Court dismisses PIL filed against Ranbaxy

25 Jun 2013 Evaluate

The Supreme Court has dismissed a public-interest litigation (PIL) filed against Ranbaxy for allegedly manufacturing and selling substandard drugs in India. The petitioner failed to bring in evidence against Ranbaxy.

Earlier in June, PIL appeal was filed in the Supreme Court against the company’s directors for allegedly manufacturing and selling adulterated drugs. Manohar Lal Sharma, the petitioner, also sought sealing of the company’s manufacturing facilities at Paonta Sahib and Devas in Madhya Pradesh, besides mentioning the Central Bureau of Investigation (CBI) as one of the respondents in the case. The PIL came in the wake of the Indian pharma major being fined $500 million by the U.S. Food and Drug Administration (USFDA) for making and selling 'adulterated' drugs

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×